PLoS Neglected Tropical Diseases (Jun 2020)

Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans.

  • Louisa Warryn,
  • Jean-Pierre Dangy,
  • Philipp Gersbach,
  • Matthias Gehringer,
  • Anja Schäfer,
  • Marie-Thérèse Ruf,
  • Nicolas Ruggli,
  • Karl-Heinz Altmann,
  • Gerd Pluschke

DOI
https://doi.org/10.1371/journal.pntd.0008357
Journal volume & issue
Vol. 14, no. 6
p. e0008357

Abstract

Read online

Mycolactones, macrolide cytotoxins, are key virulence factors of Mycobacterium ulcerans, the etiological agent of the chronic necrotizing skin disease Buruli ulcer. There is urgent need for a simple point-of-care laboratory test for Buruli ulcer and mycolactone represents a promising target for the development of an immunological assay. However, for a long time, all efforts to generate mycolactone-specific antibodies have failed. By using a protein conjugate of a truncated non-toxic synthetic mycolactone derivative, we recently described generation of a set of mycolactone-specific monoclonal antibodies. Using the first mycolactone-specific monoclonal antibodies that we have described before, we were able to develop an antigen competition assay that detects mycolactones. By the systematic selection of a capturing antibody and a reporter molecule, and the optimization of assay conditions, we developed an ELISA that detects common natural variants of mycolactone with a limit of detection in the low nanomolar range. The mycolactone-specific ELISA described here will be a very useful tool for research on the biology of this macrolide toxin. After conversion into a simple point-of-care test format, the competition assay may have great potential as laboratory assay for both the diagnosis of Buruli ulcer and for the monitoring of treatment efficacy.